Have a feature idea you'd love to see implemented?
Let us know!
IMNN Imunon Inc
Price (delayed)
$0.9552
Market cap
$13.76M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.92
Enterprise value
$9.84M
Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of
Highlights
The company's EPS rose by 49% YoY and by 5% QoQ
The net income has grown by 41% YoY and by 4.1% from the previous quarter
IMNN's debt is down by 8% from the previous quarter but it is up by 2.1% YoY
Imunon's revenue has plunged by 100% YoY
The company's gross profit has shrunk by 100% YoY
Key stats
What are the main financial stats of IMNN
Market
Valuations
Earnings
Shares outstanding
14.4M
Market cap
$13.76M
Enterprise value
$9.84M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.4
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$19.36M
EBITDA
-$18.66M
Free cash flow
-$18.88M
Per share
Balance sheet
Liquidity
EPS
-$1.92
Free cash flow per share
-$2.01
Book value per share
$0.4
Revenue per share
$0
TBVPS
$1.03
Total assets
$9.69M
Total liabilities
$5.95M
Debt
$1.39M
Equity
$3.74M
Working capital
$2.57M
Debt to equity
0.37
Current ratio
1.51
Quick ratio
1.05
Net debt/EBITDA
0.21
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-102.5%
Return on equity
-165.5%
Return on invested capital
-277.9%
Return on capital employed
-419.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IMNN stock price
How has the Imunon stock price performed over time
Intraday
-1.55%
1 week
-4.47%
1 month
-7.26%
1 year
-4.48%
YTD
40.47%
QTD
-9.89%
Financial performance
How have Imunon's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$19.9M
Net income
-$18.08M
Gross margin
N/A
Net margin
N/A
Imunon's revenue has plunged by 100% YoY
The company's gross profit has shrunk by 100% YoY
The net income has grown by 41% YoY and by 4.1% from the previous quarter
IMNN's operating income is up by 18% YoY and by 2.3% QoQ
Growth
What is Imunon's growth rate over time
Valuation
What is Imunon stock price valuation
P/E
N/A
P/B
2.4
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 49% YoY and by 5% QoQ
IMNN's price to book (P/B) is 88% higher than its 5-year quarterly average of 1.3 and 74% higher than its last 4 quarters average of 1.4
The equity has dropped by 83% year-on-year and by 56% since the previous quarter
Imunon's revenue has plunged by 100% YoY
Efficiency
How efficient is Imunon business performance
IMNN's ROIC has shrunk by 134% YoY and by 54% QoQ
The ROE has plunged by 61% YoY and by 35% from the previous quarter
Imunon's return on assets has decreased by 47% YoY and by 22% QoQ
Dividends
What is IMNN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IMNN.
Financial health
How did Imunon financials performed over time
The total assets is 63% more than the total liabilities
Imunon's quick ratio has plunged by 73% YoY and by 49% from the previous quarter
The total assets has plunged by 66% YoY and by 32% from the previous quarter
IMNN's debt is 63% less than its equity
IMNN's debt to equity has soared by 106% QoQ
The equity has dropped by 83% year-on-year and by 56% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.